Wendtner CM, Al-Sawaf O, Binder M, Dreger P, Eichhorst B, Gregor M, et al. Onkopedia Guidelines für CLL. 2023.

Google Scholar 

Hillmen P, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt, et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study. ASH 2023. p. Abstract 631.

Eichhorst B, Niemann C, Kater A, Fürstenau M, Von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54.

Article  CAS  PubMed  Google Scholar 

Fürstenau M, Ritgen M, Robrecht S, Von Tresckow J, Zhang C, Schilhabel A, et al. First-line venetoclax combinations in fit patients with CLL: 4‑year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial. ASH 2023. p. Abstract 635.

Moreno C, Munir T, Owen C, Follows G, Hernandez Rivas JA, Benjamini O, et al. First-line fixed-duration Ibrutinib plus Venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the glow study. Abstract 634. ASH 2023.

Sharman J, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in treatment-naive chronic lymphocytic leukemia: 6‑year follow-up of elevate-TN. ASH 2023. p. Abstract 636.

Tam C, Anderson MA, Lasica M, Verner E, Opat S, Ma S, et al. Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study. ASH 2023, Abstract 327

Brown J, Eichhorst B, Lamanna N, O´Brien S, Tam C, Qiu L, et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus Ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic Lymphoma (R/R CLL/SLL). ASH 2023. p. Abstract 202.

Woyach J, Brown J, Ghia P, Roeker L, Patel K, Eyre T, et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023. p. Abstract 325.

Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, et al. Tislelizumab plus zanubrutinib in patients with richter transformation: primary endpoint analysis of the prospective, multi-center, phase-II RT1 trial of the German CLL study group. ASH 2023. p. Abstract 204.